In glioma, the methylation status of the O6-methylguanine-DNA methyltransferase (MGMT) promotor is associated with the response to temozolomide treatment (Aoki and Natsume, 2019; Mathur et al., 2020). The gene discussed is MGMT; the disease is glioma.